Bio‑Techne posts flat revenue, stronger margins via cost programs and Asia expansion
- Bio‑Techne reported Q2 revenue $295.9M flat YoY; GAAP operating income +15%, adjusted margin 31.1%.
- Bio‑Techne says productivity and cost programs lifted margins; China/APAC grew third quarter, large pharma had double‑digit growth.
- Bio‑Techne focuses on Asia expansion and diversified reagents/tools to accelerate innovation; declared $0.08 quarterly dividend.
Stabilizing sales and stronger margins underpin Bio‑Techne’s near-term strategy
Bio‑Techne posts a quarter of steady revenue and improving profitability as it leans on cost programs and regional execution to sustain growth across its life‑sciences portfolio. Management reports net revenue of $295.9 million for the quarter ended Dec. 31, 2025, essentially flat year‑over‑year after a roughly 2% favorable foreign currency impact offsets a prior‑year non‑recurring revenue item. GAAP operating income rises to $54.5 million, up 15%, while adjusted earnings per share increase to $0.46 from $0.42 and adjusted operating margin expands 100 basis points to 31.1%.
Productivity initiatives and targeted commercial efforts drive the improvement
Company executives attribute margin gains to ongoing productivity and cost‑containment measures that boost operating leverage across reagents, instruments and services used in drug discovery and clinical diagnostics. Commercial execution produces regional strength, with China and APAC recording their third consecutive quarter of growth and Bio‑Techne’s largest end market, large pharma, delivering double‑digit growth for a fourth consecutive quarter. Management also notes improving biotech performance and stabilization among U.S. academic customers, reflecting a portfolio that supports high‑value applications in science and medicine.
Strategy emphasizes Asia expansion and diversified portfolio to accelerate innovation
Bio‑Techne says it is focused on sustaining growth across biopharma customers, expanding its presence in Asia and leveraging its diversified catalog of bioactive reagents and tools to accelerate innovation and clinical testing accuracy. CEO Kim Kelderman highlights continued execution in a stabilizing operating environment as the company marks its 50th anniversary in 2026. Leadership plans to review full‑year guidance and outline updated strategic priorities with investors during a scheduled call.
Quarterly dividend declared as capital policy stays conservative
The board declares a quarterly cash dividend of $0.08 per share for the quarter ended Dec. 31, 2025, payable Feb. 27, 2026, to holders of record on Feb. 16, 2026, and states that future cash dividends will be considered quarterly as part of its capital allocation framework.
Forward‑looking caveats and investor contact
The company cautions that forward‑looking items, including any share repurchases, face risks such as branding, acquisition integration, competition, pricing pressure, supply‑chain disruptions, currency swings and R&D outcomes, and directs stakeholders to its SEC filings for more detail. The release is issued from Minneapolis on Feb. 4, 2026; further information and media or investor contacts are available through David Clair, Vice President, Investor Relations, and at www.bio‑techne.com.